MediWound (NSDQ:MDWD) today announced a $25.2 million offering to support research and development of its EscharEx topical biological drug for debridement of chronic and other hard-to-heal wounds.
In the offering, the Israel-based company floated approximately 5 million shares, including 637,664 shares through an underwriter’s option.
Read the whole story on our sister site, Drug Delivery Business